Open Access

Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)

  • Authors:
    • Jing Yuan
    • Hua Lan
    • Xiaoyan Jiang
    • Da Zeng
    • Songshu Xiao
  • View Affiliations

  • Published online on: July 29, 2020     https://doi.org/10.3892/ijmm.2020.4689
  • Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemoresistance to platinum‑based chemotherapy for ovarian cancer in the advanced stage remains a formidable concern clinically. Increasing evidence has revealed that apoptosis represents the terminal events of the anti‑tumor mechanisms of a number of chemical drugs and has a close association with chemoresistance in ovarian cancer. The B‑cell lymphoma‑2 (Bcl‑2) family plays a crucial role in apoptosis and has a close association with chemoresistance in ovarian cancer. Some drugs that target Bcl‑2 family members have shown efficacy in overcoming the chemoresistance of ovarian cancer. A BH3 profiling assay was found to be able to predict how primed a cell is when treated with antitumor drugs. The present review summarizes the role of the Bcl‑2 family in mediating cell death in response to antitumor drugs and novel drugs that target Bcl‑2 family members. The application of the new functional assay, BH3 profiling, is also discussed herein. Furthermore, the present review presents the hypothesis that targeting Bcl‑2 family members may prove to be helpful for the individualized therapy of ovarian cancer in clinical practice and in laboratory research.

Related Articles

Journal Cover

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yuan J, Lan H, Jiang X, Zeng D and Xiao S: Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review). Int J Mol Med 0: 0-0, 1899
APA
Yuan, J., Lan, H., Jiang, X., Zeng, D., & Xiao, S. (1899). Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review). International Journal of Molecular Medicine, 0, 0-0. https://doi.org/10.3892/ijmm.2020.4689
MLA
Yuan, J., Lan, H., Jiang, X., Zeng, D., Xiao, S."Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)". International Journal of Molecular Medicine 0.0 (1899): 0-0.
Chicago
Yuan, J., Lan, H., Jiang, X., Zeng, D., Xiao, S."Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)". International Journal of Molecular Medicine 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ijmm.2020.4689